Asad Haider
Stock Analyst at Goldman Sachs
(2.27)
# 2,646
Out of 4,896 analysts
6
Total ratings
100%
Success rate
6.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Initiates: Neutral | $110 | $112.96 | -2.62% | 1 | May 29, 2025 | |
| JNJ Johnson & Johnson | Upgrades: Buy | $157 → $172 | $156.90 | +9.62% | 1 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $793.01 | +11.98% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $192.45 | +0.81% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $46.86 | +17.37% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $25.65 | -2.53% | 1 | Apr 8, 2025 |
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $112.96
Upside: -2.62%
Johnson & Johnson
Apr 9, 2025
Upgrades: Buy
Price Target: $157 → $172
Current: $156.90
Upside: +9.62%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $793.01
Upside: +11.98%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $192.45
Upside: +0.81%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $46.86
Upside: +17.37%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $25.65
Upside: -2.53%